fbpx

Viatris, Mylan EpiPen Market Antitrust and RICO Violations Complaint

October 29, 2021

The sharp rise in the cost of EpiPens has been in the news as an example of the astronomical inflation of the cost of drugs. This case brings antitrust claims against Viatris, Inc. (the successor-in-interest to Mylan, NV), Mylan Specialty, LP, Mylan Pharmaceuticals, Inc. and Heather Bresch, alleging that “millions of American relying on this life-saving device have paid exorbitant prices for EpiPens that are in no way tethered to or constrained by a competitive market.” In addition, the already-expensive EpiPens are now sold only in two-packs.

Case Event File: Viatris, Mylan EpiPen Market Antitrust and RICO Violations Complaint

Related to: Viatris, Mylan EpiPen Market Antitrust and RICO Violations Class Action